|
1 Discovery of the Outer Membrane Vesicles: Revisiting Contemporary Works |
|
|
1 | (14) |
|
|
|
1 | (1) |
|
|
|
2 | (1) |
|
|
|
3 | (3) |
|
1.4 A Novel Secretion Process |
|
|
6 | (2) |
|
1.5 Bleb Formation Under Abnormal Vis-a-Vis Normal Growth Conditions |
|
|
8 | (1) |
|
|
|
9 | (1) |
|
1.7 Further Work on Bleb Formation |
|
|
10 | (1) |
|
1.8 Confirmation of the Discovery by Contemporary Investigators |
|
|
11 | (1) |
|
1.9 Essential Findings of the Discovery Vis-a-Vis Later Works |
|
|
11 | (1) |
|
|
|
12 | (3) |
|
2 Gram-Negative Bacteria: The cell Membranes |
|
|
15 | (20) |
|
2.1 Inner and Outer Membranes |
|
|
15 | (3) |
|
|
|
18 | (1) |
|
2.3 Chemical Composition of OMVs |
|
|
19 | (1) |
|
2.4 Proteomic Profile of OMVs |
|
|
20 | (10) |
|
2.4.1 Isolation and Purification |
|
|
20 | (8) |
|
|
|
28 | (2) |
|
|
|
30 | (5) |
|
3 Factors Affecting Production of Outer Membrane Vesicles |
|
|
35 | (12) |
|
3.1 Natural and Unnatural OMVs |
|
|
35 | (1) |
|
3.2 Pathogenic and Nonpathogenic Bacteria |
|
|
36 | (1) |
|
3.3 Bacterial Growth Conditions |
|
|
37 | (1) |
|
3.4 Impact of LPS Structure |
|
|
38 | (1) |
|
3.5 Vesicle Production Within the Infected Host |
|
|
38 | (1) |
|
3.6 Antibiotic Treatment and Vesicle Formation |
|
|
39 | (1) |
|
3.7 Stress Response and OMV Production |
|
|
40 | (1) |
|
|
|
41 | (6) |
|
4 Outer Membrane Vesicles as Carriers of Biomaterials |
|
|
47 | (18) |
|
4.1 Packaging and Predatory Activities |
|
|
47 | (1) |
|
|
|
48 | (4) |
|
4.3 Non-Toxin Virulence Factors |
|
|
52 | (2) |
|
4.4 Enrichment of Virulence Factors in OMVs |
|
|
54 | (1) |
|
|
|
55 | (1) |
|
|
|
56 | (1) |
|
4.7 Engineered Recombinant OMVs |
|
|
57 | (3) |
|
|
|
60 | (5) |
|
5 Outer Membrane Vesicles and the Biofilm Formation |
|
|
65 | (6) |
|
|
|
68 | (3) |
|
6 Outer Membrane Vesicles: Interaction with Prokaryotes and Eukaryotes |
|
|
71 | (10) |
|
6.1 Binding with Target Cells Membrane |
|
|
74 | (1) |
|
6.2 Fusion with Target Cell Membrane |
|
|
75 | (1) |
|
6.3 Entry into the Target Cells |
|
|
75 | (2) |
|
|
|
77 | (4) |
|
7 Biogenesis of Outer Membrane Vesicles |
|
|
81 | (10) |
|
7.1 Model of OMV Biogenesis |
|
|
85 | (3) |
|
|
|
88 | (3) |
|
8 Release of Outer Membrane Vesicles: Is it a Novel Secretion Mechanism? |
|
|
91 | (4) |
|
|
|
93 | (2) |
|
9 Outer Membrane Vesicles: Physiological Medical Applications |
|
|
95 | (52) |
|
9.1 Activation of Innate Immune Response |
|
|
95 | (1) |
|
9.2 B-Cell Activation by OMVs |
|
|
96 | (3) |
|
9.3 Interaction of OMVs with Complement System |
|
|
99 | (2) |
|
9.4 OMV Triggers Cell-Mediated Immunity |
|
|
101 | (1) |
|
9.5 OMV Stimulates Proinflammatory Response |
|
|
102 | (2) |
|
|
|
104 | (14) |
|
9.6.1 Neisseria meningitidis |
|
|
105 | (3) |
|
9.6.2 Neisseria lactamica |
|
|
108 | (1) |
|
|
|
109 | (1) |
|
9.6.4 Acinetobacter baumannii |
|
|
110 | (1) |
|
9.6.5 Bordetella pertussis |
|
|
111 | (1) |
|
9.6.6 Burkholderia pseudomallei |
|
|
112 | (1) |
|
9.6.7 Porphyromonas gingivalis |
|
|
113 | (1) |
|
9.6.8 Salmonella typhimurium |
|
|
114 | (2) |
|
|
|
116 | (1) |
|
9.6.10 Treponema pallidum |
|
|
117 | (1) |
|
|
|
118 | (17) |
|
9.7.1 OMVs as Vaccines for Meningococcal Diseases |
|
|
119 | (1) |
|
9.7.2 Markers of Protection Against Meningococcal Disease |
|
|
119 | (1) |
|
9.7.3 Challenges for Vaccine Development |
|
|
120 | (1) |
|
9.7.4 Detergent-Treated OMVs as Vaccine |
|
|
120 | (5) |
|
9.7.5 Native OMVs as Vaccine |
|
|
125 | (2) |
|
9.7.6 OMV Vaccines in Combination |
|
|
127 | (3) |
|
9.7.7 Recombinant OMV Vaccines Using Reverse Vaccinology Approach |
|
|
130 | (3) |
|
9.7.8 OMVs in Vaccine Delivery |
|
|
133 | (1) |
|
|
|
133 | (1) |
|
9.7.10 OMV as Controlled Release System for Vaccine |
|
|
134 | (1) |
|
|
|
135 | (12) |
|
|
|
147 | (4) |
| Index |
|
151 | |
Lisainfo e-raamatute kohta